Skip to main content
. Author manuscript; available in PMC: 2009 Jan 1.
Published in final edited form as: Expert Opin Med Diagn. 2008 Jul;2(7):829–842. doi: 10.1517/17530059.2.7.829

Figure 3.

Figure 3

Whole body planar images of a trastuzumab naive patient with HER2+ metastatic breast cancer 4 hours following 5mCi IV injection of 111In trastuzumab. The solid arrows demonstrate uptake in patients known bony metastases. Intense uptake in the liver is physiologic (primary route of excretion). The hollow arrow indicates the location of 5 microCi source external to the patients, placed for calibration.